表紙
市場調查報告書

血漿分餾製劑的全球市場 - 至2024年的預測:免疫球蛋白,白蛋白,第九凝血因子,馮威里氏因子 (VWF),凝血酵素原複合物濃縮劑 (PCC),蛋白分解酵素抑制劑

Plasma Fractionation Market by Product[IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application(Immunology, Hematology, Critical Care, Rheumatology) End User(Hospital/Clinic/Academic Institute)-Global Forecast to 2024

出版商 MarketsandMarkets 商品編碼 365863
出版日期 內容資訊 英文 301 Pages
訂單完成後即時交付
價格
Back to Top
血漿分餾製劑的全球市場 - 至2024年的預測:免疫球蛋白,白蛋白,第九凝血因子,馮威里氏因子 (VWF),凝血酵素原複合物濃縮劑 (PCC),蛋白分解酵素抑制劑 Plasma Fractionation Market by Product[IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application(Immunology, Hematology, Critical Care, Rheumatology) End User(Hospital/Clinic/Academic Institute)-Global Forecast to 2024
出版日期: 2019年03月28日內容資訊: 英文 301 Pages
簡介

全球血漿分餾製劑市場,預計從2019年的254億美元,到2024年達349億美元。預計市場2019年∼2024年以6.6%的年複合成長率成長。

本報告提供全球血漿分餾製劑市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 血漿分餾製劑市場概要
  • 血漿分餾製劑市場各地區概述
  • 血漿分餾製劑市場:地區結構
  • 血漿分餾製劑市場:發展中國家 vs. 已開發國家

第5章 市場概要

  • 簡介
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
    • 市場課題

第6章 產業考察

  • 簡介
  • 主要產業趨勢
  • 波特的五力分析
  • 供應商的基準
  • 價格分析

第7章 血漿分餾製劑的全球市場:各產品

  • 簡介
  • 免疫球蛋白
  • 凝血因子濃縮製劑
  • 白蛋白
  • 蛋白分解酵素抑制劑
  • 其他

第8章 血漿分餾製劑的全球市場:各適應症

  • 簡介
  • 神經症
  • 免疫疾病
  • 血液疾病
  • 重症加護
  • 肺部疾病
  • 血液腫瘤
  • 風濕
  • 其他

第9章 血漿分餾製劑的全球市場:各終端用戶

  • 簡介
  • 醫院、診所
  • 臨床研究所
  • 學術機構

第10章 血漿分餾製劑的全球市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第11章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭領導製圖
  • 競爭模式與趨勢

第12章 企業簡介

  • CSL
  • GRIFOLS
  • SHIRE
  • OCTAPHARMA
  • KEDRION
  • LFB
  • BIOTEST
  • SANQUIN
  • CHINA BIOLOGIC PRODUCTS
  • BIO PRODUCTS LABORATORY (BPL)
  • 日本血液製劑機構
  • GC PHARMA (GREEN CROSS CORPORATION)
  • SHANGHAI RAAS BLOOD PRODUCTS

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PH 4477

"Global plasma fractionation market is projected to grow at a CAGR of 6.6%."

The global plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. Growth in the plasma fractionation market can largely be attributed to factors such as the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.

"By product, immunoglobulin market is expected to hold the largest share of the plasma fractionation market in 2019."

The immunoglobulin segment is expected to dominate the plasma fractionation market during the forecast period. IVIg is the most extensively used plasma product across the globe, meant for the treatment of dermatomyositis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, and systemic lupus erythematosus, among other ailments. The growing prevalence of these and other target diseases, as a result, is the key driver of market growth.

"Factor VIII will dominate the coagulation factor concentrates market in 2019."

The coagulation factor market is segmented into factor VIII, factor IX, Von Willebrand factor, prothrombin factor concentrates, fibrinogen concentrates, and factor XIII. Factor VIII segment is expected to hold the largest share in the coagulation factor concentrates market in 2019. This is attributed to the growth in geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies for a majority of hemophilia patients in developing countries is also expected to drive this market.

"North America is expected to hold the largest share during the forecast period (2019-2024)"

North America is expected to dominate the plasma fractionation market during the forecast period. The demand for plasma products in North America is mainly driven by the increasing use of immunoglobulins in neurological and autoimmune diseases and the increasing use of prophylaxis treatments among diagnosed patients. The rising number of registered hemophilic patients (as illustrated in the table below) is also propelling the growth of this market. The growing number of hemophilic patients will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America.

A breakdown of supply-side primary participants is mentioned below:

  • By Company Type: Tier 1-38%, Tier 2-21%, and Tier 3-41%
  • By Designation: C-level-30%, Director Level-28%, Others-42%
  • By Region: North America-35%, Europe-25%, Asia Pacific-20%, Latin America-12%, Middle East and Africa-8%

Major players in the global plasma fractionation market include: CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).

Research Coverage:

The plasma fractionation market in this report is segmented by product, application, end user, and region. It provides detailed information regarding the major factors influencing the growth market (drivers, restraints, opportunities, and industry-specific challenges). The study tracks and analyzes competitive developments (such as partnerships, agreements, collaborations, mergers & acquisitions, product developments, geographical expansions, and R&D activities) and strategically profiles the key players and comprehensively analyzes their market shares and core competencies in the plasma fractionation market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis-the market share analysis of top players in the global market, different product segments, as well on the regional levels, company profiles that comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the plasma fractionation market; high-growth regions; and market drivers, restraints, and opportunities. The report provides the latest statistics and industry trends, allowing buyers to identify high-growth product segments and potential customers and suppliers, hence driving revenue growth and profitability. The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on products offered by the top players in the global plasma fractionation market
  • Product Development/Innovation: Detailed insights on growth strategies, research & development activities, and product launches in the global plasma fractionation market
  • Market Development: Comprehensive information about lucrative emerging markets-the report analyzes the markets for plasma fractionation across regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global plasma fractionation market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global plasma fractionation market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 SCOPE OF THE STUDY
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY SOURCES
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY SOURCES
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 PLASMA FRACTIONATION MARKET OVERVIEW
  • 4.2 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET
  • 4.3 PLASMA FRACTIONATION MARKET: REGIONAL MIX
  • 4.4 PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS. DEVELOPED COUNTRIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Growing use of immunoglobulins in various therapeutic areas
      • 5.2.1.2 Rising geriatric population across the globe
      • 5.2.1.3 Growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin
      • 5.2.1.4 Increase in plasma collection
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 High cost and limited reimbursement
      • 5.2.2.2 Emergence of recombinant alternatives
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Rising prevalence of bleeding disorders
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Stringent government regulations

6 INDUSTRY INSIGHTS

  • 6.1 INTRODUCTION
  • 6.2 KEY INDUSTRY TRENDS
    • 6.2.1 FOCUS ON INCREASING FRACTIONATION CAPACITIES
    • 6.2.2 NEW INDICATIONS FOR PLASMA PRODUCTS
    • 6.2.3 RISING ADOPTION OF SCIG
    • 6.2.4 INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS
    • 6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA
    • 6.2.6 INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS
  • 6.3 PORTER'S FIVE FORCES
    • 6.3.1 THREAT OF NEW ENTRANTS
    • 6.3.2 THREAT OF SUBSTITUTES
    • 6.3.3 BARGAINING POWER OF SUPPLIERS
    • 6.3.4 BARGAINING POWER OF BUYERS
    • 6.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 6.4 VENDOR BENCHMARKING
    • 6.4.1 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET
    • 6.4.2 NO. OF PLASMA COLLECTION CENTERS AND FRACTIONATION CAPACITIES, BY KEY PLAYER
    • 6.4.3 BUSINESS PRESENCE OF KEY PLAYERS IN THE VALUE CHAIN
  • 6.5 PRICING ANALYSIS

7 PLASMA FRACTIONATION MARKET, BY PRODUCT

  • 7.1 INTRODUCTION
  • 7.2 IMMUNOGLOBULINS
    • 7.2.1 INTRAVENOUS IMMUNOGLOBULINS
      • 7.2.1.1 IVIg holds the largest share of the immunoglobulins market
    • 7.2.2 SUBCUTANEOUS IMMUNOGLOBULINS
      • 7.2.2.1 Benefit of self-administration and lower incidence of non-serious systemic adverse reactions will drive the growth of the SCIg market
    • 7.2.3 OTHER IMMUNOGLOBULINS
  • 7.3 COAGULATION FACTOR CONCENTRATES
    • 7.3.1 FACTOR VIII
      • 7.3.1.1 Factor VIII holds the largest share of the coagulation factor concentrates market
    • 7.3.2 FACTOR IX
      • 7.3.2.1 Growth in the aging population and the rise in the number of hemophilic patients is expected to drive the growth in this market
    • 7.3.3 VON WILLEBRAND FACTOR
      • 7.3.3.1 Market growth is primarily driven by the increasing prevalence and diagnosis of Von Willebrand disease and hemophilia
    • 7.3.4 PROTHROMBIN COMPLEX CONCENTRATE
      • 7.3.4.1 Advantages of PCC over fresh frozen plasma will support market growth in this segment
    • 7.3.5 FIBRINOGEN CONCENTRATES
      • 7.3.5.1 Safety profile, accuracy, and speed of administration have supported the growth of the fibrinogen concentrates market
    • 7.3.6 FACTOR XIII
      • 7.3.6.1 Applications in treating rare bleeding disorders will contribute to the demand for Factor XIII
  • 7.4 ALBUMIN
    • 7.4.1 WIDE DEMAND FOR ALBUMIN AS AN ANTIOXIDANT AND VOLUME EXPANDER WILL DRIVE MARKET GROWTH
  • 7.5 PROTEASE INHIBITORS
    • 7.5.1 INCREASING GLOBAL DISEASE BURDEN WILL DRIVE DEMAND FOR PROTEASE INHIBITORS
  • 7.6 OTHER PRODUCTS

8 PLASMA FRACTIONATION MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 NEUROLOGY
    • 8.2.1 RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE THIS MARKET
  • 8.3 IMMUNOLOGY
    • 8.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS TO DRIVE THE GROWTH OF THIS MARKET

  • 8.4 HEMATOLOGY
    • 8.4.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS
  • 8.5 CRITICAL CARE
    • 8.5.1 INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS
  • 8.6 PULMONOLOGY
    • 8.6.1 RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY
  • 8.7 HEMATO-ONCOLOGY
    • 8.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS IN HEMATO-ONCOLOGY
  • 8.8 RHEUMATOLOGY
    • 8.8.1 INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY
  • 8.9 OTHER APPLICATIONS

9 PLASMA FRACTIONATION MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS & CLINICS
    • 9.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWTH IN THE NUMBER OF HOSPITALS & CLINICS-KEY FACTORS DRIVING GROWTH
  • 9.3 CLINICAL RESEARCH LABORATORIES
    • 9.3.1 INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE THE MARKET FOR CLINICAL RESEARCH LABORATORIES
  • 9.4 ACADEMIC INSTITUTES
    • 9.4.1 INCREASING BASIC MEDICAL RESEARCH ACTIVITIES AND GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES

10 PLASMA FRACTIONATION MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 US
      • 10.2.1.1 The US dominates the global plasma fractionation market
    • 10.2.2 CANADA
      • 10.2.2.1 Canada is one of the world's highest per capita users of IVIg
  • 10.3 EUROPE
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany has the highest plasma fractionation capacity in Europe
    • 10.3.2 FRANCE
      • 10.3.2.1 High prevalence of bleeding disorders to drive the market for plasma fractionation in France

    • 10.3.3 ITALY
      • 10.3.3.1 Growth in the country's geriatric population to drive the market for plasma fractionation
    • 10.3.4 SPAIN
      • 10.3.4.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth
    • 10.3.5 UK
      • 10.3.5.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK
    • 10.3.6 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 CHINA
      • 10.4.1.1 Significant growth in the incidence of diseases such as hypoalbuminemia, liver cancer, and hepatitis B are driving the growth of plasma-derived products market in China
    • 10.4.2 JAPAN
      • 10.4.2.1 The rising geriatric population is expected to increase the prevalence of neurological disorders and hematological diseases in Japan in the coming years
    • 10.4.3 AUSTRALIA
      • 10.4.3.1 High production of plasma products and the growing demand for plasma products for the treatment of chronic disease to drive market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth
    • 10.4.5 VIETNAM
      • 10.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth
    • 10.4.6 INDONESIA
      • 10.4.6.1 Growing government initiatives to drive market growth
    • 10.4.7 MALAYSIA
      • 10.4.7.1 Growing healthcare awareness, increasing prevalence of bleeding disorders, and the rising geriatric population are the major factors driving market growth
    • 10.4.8 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES, RISING GERIATRIC POPULATION, AND INCREASING INCIDENCE OF BLEEDING DISORDERS TO DRIVE MARKET GROWTH IN LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 TURKEY
      • 10.6.1.1 Turkey dominated the plasma fractionation market in the Middle East and Africa
    • 10.6.2 SAUDI ARABIA
      • 10.6.2.1 Rising use of immunoglobulins in neurology and immunology and the strengthening of healthcare infrastructure to drive market growth
    • 10.6.3 EGYPT
      • 10.6.3.1 Growing research on plasma and plasma derivatives and the increasing adoption of plasma products to drive market growth
    • 10.6.4 UAE
      • 10.6.4.1 Increasing incidence of bleeding disorders and growing government initiatives for healthcare infrastructure development to drive market growth
    • 10.6.5 REST OF MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET SHARE ANALYSIS
    • 11.2.1 MARKET SHARE ANALYSIS, BY PRODUCT,2018
      • 11.2.1.1 Immunoglobulin market, by key players
        • 11.2.1.1.1 IVIG market, by key players
      • 11.2.1.2 Coagulation factor market, by key players
        • 11.2.1.2.1 Factor VIII market, by key players
      • 11.2.1.3 Albumin market, by key players
    • 11.2.2 MARKET SHARE ANALYSIS, BY REGION,2018
      • 11.2.2.1 North America plasma fractionation market, by key players
        • 11.2.2.1.1 US plasma fractionation market, by key players
      • 11.2.2.2 Europe plasma fractionation market, by key players
  • 11.3 COMPETITIVE LEADERSHIP MAPPING
    • 11.3.1 VISIONARY LEADERS
    • 11.3.2 INNOVATORS
    • 11.3.3 DYNAMIC DIFFERENTIATORS
    • 11.3.4 EMERGING COMPANIES
  • 11.4 COMPETITIVE SCENARIO AND TRENDS
    • 11.4.1 PRODUCT LAUNCHES/APPROVALS
    • 11.4.2 EXPANSIONS
    • 11.4.3 ACQUISITIONS
    • 11.4.4 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 12.1 CSL
  • 12.2 GRIFOLS
  • 12.3 SHIRE
  • 12.4 OCTAPHARMA
  • 12.5 KEDRION
  • 12.6 LFB
  • 12.7 BIOTEST
  • 12.8 SANQUIN
  • 12.9 CHINA BIOLOGIC PRODUCTS
  • 12.10 BIO PRODUCTS LABORATORY (BPL)
  • 12.11 JAPAN BLOOD PRODUCTS ORGANIZATION
  • 12.12 GC PHARMA (GREEN CROSS CORPORATION)
  • 12.13 SHANGHAI RAAS BLOOD PRODUCTS

Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INSIGHTS OF INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 AVAILABLE CUSTOMIZATION
  • 13.4 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.5 RELATED REPORT
  • 13.6 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS
  • TABLE 2: ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG
  • TABLE 3: NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION, 2017
  • TABLE 4: NUMBER OF PATIENTS TREATED FOR TOP 10 TARGET CONDITIONS IN THE UK (2015-16)
  • TABLE 5: INCREASE IN GERIATRIC POPULATION FROM 2000 TO 2050 ACROSS THE GLOBE
  • TABLE 6: NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2018
  • TABLE 7: NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2017
  • TABLE 8: FRACTIONATION CAPACITY EXPANSIONS BY MAJOR PLAYERS
  • TABLE 9: PER CAPITA CONSUMPTION OF IVIG AND ALBUMIN, BY COUNTRY (2014)
  • TABLE 10: CHINA: TOP PLAYERS IN THE PLASMA FRACTIONATION MARKET, 2018
  • TABLE 11: MAJOR LOCAL PLAYERS IN CHINA
  • TABLE 12: REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON PLASMA-DERIVED PRODUCTS
  • TABLE 13: AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY PLAYER (2018)
  • TABLE 14: AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION (2018)
  • TABLE 15: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 16: IVIG VS. SCIG THERAPY
  • TABLE 17: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 18: IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 19: INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
  • TABLE 20: INTRAVENOUS IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 21: INTRAVENOUS IMMUNOGLOBULINS MARKET, BY REGION, 2017-2024 (METRIC TONS)
  • TABLE 22: SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
  • TABLE 23: SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 24: SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY REGION, 2017-2024 (METRIC TONS)
  • TABLE 25: OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
  • TABLE 26: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 27: OTHER IMMUNOGLOBULINS MARKET, BY REGION, 2017-2024 (MILLION INTERNATIONAL UNITS)
  • TABLE 28: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 29: COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 30: FACTOR VIII OFFERED BY KEY MARKET PLAYERS
  • TABLE 31: FACTOR VIII MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 32: FACTOR VIII MARKET, BY REGION, 2017-2024 (MILLION INTERNATIONAL UNITS)
  • TABLE 33: FACTOR IX OFFERED BY KEY MARKET PLAYERS
  • TABLE 34: FACTOR IX MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 35: VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS
  • TABLE 36: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 37: PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS
  • TABLE 38: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 39: FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS
  • TABLE 40: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 41: FACTOR XIII OFFERED BY KEY MARKET PLAYERS
  • TABLE 42: FACTOR XIII MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 43: ALBUMIN OFFERED BY KEY MARKET PLAYERS
  • TABLE 44: ALBUMIN MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 45: GLOBAL ALBUMIN MARKET, BY REGION, 2017-2024 (METRIC TONS)
  • TABLE 46: PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS
  • TABLE 47: PROTEASE INHIBITORS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 48: OTHER PRODUCTS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 49: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 50: NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030
  • TABLE 51: PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY
  • TABLE 52: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 53: LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY
  • TABLE 54: PRIMARY IMMUNODEFICIENCY DISEASE, BY TYPE
  • TABLE 55: PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION, 2013 VS. 2015
  • TABLE 56: PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY
  • TABLE 57: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 58: NUMBER OF HEMOPHILIA PATIENTS (2012-2017)
  • TABLE 59: PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY
  • TABLE 60: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 61: PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE
  • TABLE 62: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 63: PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY
  • TABLE 64: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 65: INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN LYMPHOMA, BY REGION, 2012 VS. 2015 VS. 2018
  • TABLE 66: PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY
  • TABLE 67: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 68: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 69: PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS
  • TABLE 70: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 71: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 72: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 73: CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN (2017)
  • TABLE 74: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 75: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 76: REGIONAL DISTRIBUTION OF PLASMA FRACTIONATION PLANTS AND PLASMA THROUGHPUT, BY REGION, 2014
  • TABLE 77: PLASMA FRACTIONATION MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 78: NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2017
  • TABLE 79: TRANSFER OF PLASMA FROM US TO OTHER REGIONS, 2014
  • TABLE 80: NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 81: NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 82: NORTH AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 83: NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 84: NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 85: NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 86: US: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 87: US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 88: US: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 89: US: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 90: US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 91: US: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 92: CANADA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 93: CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 94: CANADA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 95: CANADA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 96: CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 97: CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 98: EUROPE: PLASMA COLLECTION, 2007-2016
  • TABLE 99: PLASMA FRACTIONATION PLANTS IN EUROPE (2017)
  • TABLE 100: EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 101: EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 102: EUROPE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 103: EUROPE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 104: EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 105: EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 106: GERMANY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 107: GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 108: GERMANY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 109: GERMANY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 110: GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 111: GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 112: NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012-2017
  • TABLE 113: FRANCE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 114: FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 115: FRANCE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 116: FRANCE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 117: FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 118: FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 119: ITALY: NUMBER OF BLOOD DONATIONS, 2011 VS. 2013
  • TABLE 120: PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018-E, & 2023-E)
  • TABLE 121: ITALY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 122: ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 123: ITALY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 124: ITALY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 125: ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 126: ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 127: SPAIN: KEY MACROINDICATORS FOR THE PLASMS FRACTIONATION MARKET
  • TABLE 128: SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 129: SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 130: SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 131: SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 132: SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 133: USAGE OF IMMUNOGLOBULINS
  • TABLE 134: ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS IN THE UK, 2012-2016
  • TABLE 135: VOLUME OF IMMUNOGLOBULINS USED FOR THE TOP 5 DIAGNOSES (2016)
  • TABLE 136: UK: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 137: UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 138: UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 139: UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 140: UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 141: UK: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 142: TOTAL NUMBER OF HEMOPHILIA PATIENTS IN REST OF EUROPE: 2012-2017
  • TABLE 143: ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 144: ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 145: ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 146: ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 147: ROE: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 148: ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 149: ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 150: ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 151: ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 152: ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 153: ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 154: CHINA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 155: CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 156: CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 157: CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 158: CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 159: CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 160: MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS. 2017 (IN IU/TOTAL POPULATION)
  • TABLE 161: PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2017
  • TABLE 162: JAPAN: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 163: JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 164: JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 165: JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 166: JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 167: JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 168: TOTAL IG (GRAMS) USED IN AUSTRALIA, 2006-2015
  • TABLE 169: AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008-2017 (USD MILLION)
  • TABLE 170: AUSTRALIA: BLOOD SECTOR OVERVIEW (2017)
  • TABLE 171: AUSTRALIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 172: AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 173: AUSTRALIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 174: AUSTRALIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 175: AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 176: AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 177: INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012-2016
  • TABLE 178: INDIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 179: INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 180: INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 181: INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 182: INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 183: INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 184: VIETNAM: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 185: VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 186: VIETNAM: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 187: VIETNAM: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 188: VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 189: VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 190: INDONESIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 191: INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 192: INDONESIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 193: INDONESIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 194: INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 195: INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 196: MALAYSIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012-2017
  • TABLE 197: MALAYSIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 198: MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 199: MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 200: MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 201: MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 202: MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 203: REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 204: REST OF ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 205: REST OF ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 206: REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 207: REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 208: BRAZIL: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 209: MEXICO: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 210: LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 211: LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 212: LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 213: LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 214: LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 215: HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA, 2012-2017
  • TABLE 216: PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION) IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012-2017
  • TABLE 217: MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 218: MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 219: MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 220: MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 221: MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 222: MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 223: TURKEY: DEMOGRAPHIC INDICATORS
  • TABLE 224: TURKEY: REPORTED CASES OF BLOOD DISORDERS, 2012 VS. 2014
  • TABLE 225: TURKEY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 226: TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 227: TURKEY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 228: TURKEY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 229: TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 230: TURKEY: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 231: ESTIMATED INCIDENCE AND PREVALENCE OF CID, SCID, AND MHC II DEFICIENCY IN CHILDREN IN SAUDI ARABIA
  • TABLE 232: PER CAPITA CONSUMPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND ALBUMIN (2015/2016)
  • TABLE 233: SAUDI ARABIA: BLOOD DISORDER CASES, BY TYPE, 2014 VS. 2016
  • TABLE 234: SAUDI ARABIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 235: SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 236: SAUDI ARABIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 237: SAUDI ARABIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 238: SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 239: SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 240: EGYPT: BLOOD DISORDER CASES, BY TYPE, 2014-2017
  • TABLE 241: EGYPT: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 242: EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 243: EGYPT: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 244: EGYPT: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 245: EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 246: EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 247: UAE: GROWTH IN THE NUMBER OF BLOOD DONORS
  • TABLE 248: UAE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
  • TABLE 249: UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 250: UAE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 251: UAE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 252: UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 253: UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 254: HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST AND AFRICA, 2012 VS. 2017
  • TABLE 255: PER CAPITA CONSUMPTION OF FACTOR IX AND VIII IN SOUTH AFRICA AND QATAR (IU/TOTAL POPULATION), 2013 VS. 2017
  • TABLE 256: ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 257: ROMEA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 258: ROMEA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 259: ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 260: ROMEA: PLASMA FRACTIONATION MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 261: GROWTH STRATEGY MATRIX
  • TABLE 262: PRODUCT LAUNCHES/APPROVALS, JANUARY 2016 TO APRIL 2019
  • TABLE 263: EXPANSIONS, JANUARY 2016 TO APRIL 2019
  • TABLE 264: ACQUISITIONS, JANUARY 2016 TO APRIL 2019
  • TABLE 265: AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2016 TO APRIL 2019

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: SUPPLY SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DEMAND SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION
  • FIGURE 4: DATA TRIANGULATION METHODOLOGY
  • FIGURE 5: IMMUNOGLOBULINS SEGMENT TO DOMINATE THE PLASMA FRACTIONATION MARKET, BY PRODUCT, FROM 2019 TO 2024
  • FIGURE 6: NEUROLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 7: PLASMA FRACTIONATION MARKET, BY END USER, 2019 VS. 2024 (USD MILLION)
  • FIGURE 8: GEOGRAPHIC SNAPSHOT: PLASMA FRACTIONATION MARKET IN 2018
  • FIGURE 9: GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
  • FIGURE 10: THE US ACCOUNTED FOR THE LARGEST SHARE OF THE PLASMA FRACTIONATION MARKET IN 2018
  • FIGURE 11: ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 12: DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
  • FIGURE 13: GLOBAL PERCENTAGE OF DEATHS FROM RESPIRATORY DISEASES, 2008 TO 2030
  • FIGURE 14: SOURCE PLASMA COLLECTION IN THE US, 2004-2017
  • FIGURE 15: PLASMA COLLECTION CENTERS IN THE US AND EUROPE, 2007-2016
  • FIGURE 16: NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE, 2012-2017
  • FIGURE 17: INCREASING CONSOLIDATION AND RISING ADOPTION OF SCIG ARE THE LEADING INDUSTRY TRENDS
  • FIGURE 18: PLASMA FRACTIONATION MARKET IN CHINA VS. US, 2017-2024
  • FIGURE 19: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 20: IMMUNOGLOBULIN SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2019 TO 2024
  • FIGURE 21: PREVALENCE OF BLEEDING DISORDERS, BY COUNTRY, 2017
  • FIGURE 22: MEAN PER CAPITA USAGE OF FACTOR VIII (2016 VS 2017)
  • FIGURE 23: MEAN PER CAPITA USAGE OF FACTOR IX (2016 VS 2017)
  • FIGURE 24: NEUROLOGY SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2019 TO 2024
  • FIGURE 25: NUMBER OF HEMOPHILIA PATIENTS IN MAJOR COUNTRIES, 2016 VS. 2017
  • FIGURE 26: HOSPITALS & CLINICS TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 27: NORTH AMERICA TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 28: PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 29: NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
  • FIGURE 30: PLASMA COLLECTION VOLUME IN THE US, 2004-2017
  • FIGURE 31: PLASMA COLLECTION CENTERS IN THE US, 2005-2017
  • FIGURE 32: EUROPE: PLASMA FRACTIONATION MARKET SNAPSHOT
  • FIGURE 33: HEMOPHILIA A & B PATIENTS IN GERMANY, 2013-2016
  • FIGURE 34: APAC: PLASMA FRACTIONATION MARKET SNAPSHOT
  • FIGURE 35: FRESH BLOOD EXPENDITURE IN AUSTRALIA, 2008-2017 (USD MILLION)
  • FIGURE 36: MEAN PER CAPITA USE OF FACTOR VIII AND IX IN VIETNAM, 2014-2017 (IU/POPULATION)
  • FIGURE 37: PATIENT POPULATION SUFFERING FROM BLEEDING DISORDERS IN VIETNAM, 2014-2017
  • FIGURE 38: BLOOD DONATION IN INDONESIA, 2011-2015 (MILLION UNITS)
  • FIGURE 39: KEY STRATEGIES ADOPTED BY PLAYERS (JANUARY 2016 TO APRIL 2019)
  • FIGURE 40: PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
  • FIGURE 41: COMPETITIVE LEADERSHIP MAPPING
  • FIGURE 42: CSL: COMPANY SNAPSHOT (2018)
  • FIGURE 43: GRIFOLS: COMPANY SNAPSHOT (2017)
  • FIGURE 44: SHIRE: COMPANY SNAPSHOT (2017)
  • FIGURE 45: OCTAPHARMA: COMPANY SNAPSHOT (2018)
  • FIGURE 46: KEDRION: COMPANY SNAPSHOT (2017)
  • FIGURE 47: LFB: COMPANY SNAPSHOT (2016)
  • FIGURE 48: BIOTEST: COMPANY SNAPSHOT (2017)
  • FIGURE 49: SANQUIN: COMPANY SNAPSHOT (2017)
  • FIGURE 50: CHINA BIOLOGIC PRODUCTS: COMPANY SNAPSHOT (2017)
  • FIGURE 51: JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2016)
  • FIGURE 52: GC PHARMA: COMPANY SNAPSHOT (2017)
Back to Top